anti dkc1 antibody  (Santa Cruz Biotechnology)

Journal: Journal of Translational Medicine

Article Title: DKC1: a robust prognostic factor and potential therapeutic target in multiple myeloma

doi: 10.1186/s12967-026-07916-6

Figure Lengend Snippet: DKC1 expression is correlated with adverse clinical features and serves as a biomarker for prognostic evaluation and disease staging in MM. A DKC1 mRNA expression in MM and PCL patients compared to MGUS patients from GSE2113 dataset. B DKC1 protein expression across healthy controls, MGUS, MM, and PCL patients. C, D DKC1 mRNA expression analysis from the MMRF CoMMpass dataset. C DKC1 mRNA expression in primary and recurrent patients. D DKC1 mRNA expression across different ISS stages. E Kaplan-Meier survival analysis of OS in MMRF CoMMpass dataset for DKC1-high ( n = 392) and DKC1-low ( n = 393) patients. F Kaplan-Meier survival curves for PFS in GSE136324 dataset for DKC1-high ( n = 218) and DKC1-low ( n = 218) patients. G, H Univariate (left) and multivariate (right) Cox regression analyses for OS ( G ) and PFS ( H ), using data from MMRF CoMMpass dataset and GSE136324 dataset respectively. I Decision tree analysis based on DKC1, B2M and ALB for risk stratification in MM patients. J Time-dependent ROC curve evaluating the predictive performance of the model over time. K Estimation of variable importance based on the decision tree model. Abbreviations: plasma cell leukemia (PCL); multiple myeloma (MM); monoclonal gammopathy of undetermined significance (MGUS); overall survival (OS); progression-free survival (PFS); β2-microglobulin (B2M); albumin (ALB); receiver operating characteristic (ROC)

Article Snippet: The following primary antibodies were used: DKC1 (A4407, ABclonal, Wuhan, China), ATF5 (AP0692, ABclonal), Bax (5023S, CST, Danvers, MA, USA), Bcl-2 (A19693, ABclonal) and β-actin (AC026, ABclonal).

Techniques: Expressing, Biomarker Discovery, Clinical Proteomics

Journal: Journal of Translational Medicine

Article Title: DKC1: a robust prognostic factor and potential therapeutic target in multiple myeloma

doi: 10.1186/s12967-026-07916-6

Figure Lengend Snippet: DKC1 promotes proliferation of MM cells. A, B EdU staining ( A ) and soft agar colony formation ( B ) of MM cells following DKC1 knockdown (shDKC1) in RPMI8226 and MM.1S cells or DKC1 overexpression (oeDKC1) in RPMI8226 cells, with corresponding control cells (MOCK1 for knockdown, MOCK2 for overexpression) (scale bar = 200 µm). C, D EdU staining ( C ) and soft agar colony formation ( D ) of MM cells treated with PF at 0.2, 0.4, and 0.8 µM, with an equivalent volume of vehicle used as the control (0 µM PF) (scale bar = 200 µm). Data are presented as mean ± SD from three independent experiments. Abbreviations: pyrazofurin (PF)

Article Snippet: The following primary antibodies were used: DKC1 (A4407, ABclonal, Wuhan, China), ATF5 (AP0692, ABclonal), Bax (5023S, CST, Danvers, MA, USA), Bcl-2 (A19693, ABclonal) and β-actin (AC026, ABclonal).

Techniques: Staining, Knockdown, Over Expression, Control

Journal: Journal of Translational Medicine

Article Title: DKC1: a robust prognostic factor and potential therapeutic target in multiple myeloma

doi: 10.1186/s12967-026-07916-6

Figure Lengend Snippet: DKC1 reduces apoptosis of MM cells. A, B Flow cytometric analysis of apoptosis in shDKC1 and MOCK1 MM cells, with ( A ) RPMI8226 cells and ( B ) MM.1S cells, using Annexin V and 7-AAD staining. C Flow cytometric analysis of apoptosis in oeDKC1 and MOCK2 MM cells following culture with or without FBS for 24, 48, and 72 h. D Apoptosis of RPMI8226 cells was assessed after treatment with PF at 0.2, 0.4, and 0.8 µM for 72 h, with an equivalent volume of vehicle used as the control (0 µM PF). Data are presented as mean ± SD from three independent experiments

Article Snippet: The following primary antibodies were used: DKC1 (A4407, ABclonal, Wuhan, China), ATF5 (AP0692, ABclonal), Bax (5023S, CST, Danvers, MA, USA), Bcl-2 (A19693, ABclonal) and β-actin (AC026, ABclonal).

Techniques: Staining, Control

Journal: Journal of Translational Medicine

Article Title: DKC1: a robust prognostic factor and potential therapeutic target in multiple myeloma

doi: 10.1186/s12967-026-07916-6

Figure Lengend Snippet: Both DKC1 knockdown and PF treatment suppress tumor growth in MM mouse model. A Experimental schematic comparing the MOCK1 and shDKC1 groups in the MM mouse model. B-D Representative tumor photographs ( B ), tumor growth curves ( C ) and tumor weights ( D ) in the MOCK1 and shDKC1 groups, with six mice per group. For panels ( C ), ** indicates p = 0.0056 at day 2, **** indicates p < 0.0001 at days 4, 6, 8, respectively for MOCK1 (blue) vs shDKC1 (red). E, F Representative immunohistochemical staining of Ki67 ( E ) and TUNEL ( F ) in MOCK1 and shDKC1 groups at × 20 magnification (scale bar = 100 µm) and × 40 magnification (scale bar = 50 µm). Data were obtained from 3 mice per group. G Schematic representation of the PF treatment regimen in the MM mouse model. Briefly, MM xenograft models were established and mice were randomized to two groups. Mice in the experimental group received PF (5 mg/kg, intraperitoneal injection, every third day), whereas those in the control group were administered vehicle. H-K Representative tumor photographs ( H ), tumor growth curves ( I ), tumor weights ( J ) and bioluminescence monitoring ( K ) of tumors in PF and vehicle groups, with five mice per group. For panel ( I ), * indicates p = 0.0218 at day 8, **** indicates p < 0.0001 at days 10, 12, respectively for vehicle (blue) vs PF (red). L, M Representative immunohistochemical staining of Ki67 ( L ) and TUNEL ( M ) in vehicle and PF groups at × 20 magnification (scale bar = 100 µm) and × 40 magnification (scale bar = 50 µm). Data were obtained from 3 mice per group. All quantitative data are presented as mean ± SD. Abbreviations: pyrazofurin (PF)

Article Snippet: The following primary antibodies were used: DKC1 (A4407, ABclonal, Wuhan, China), ATF5 (AP0692, ABclonal), Bax (5023S, CST, Danvers, MA, USA), Bcl-2 (A19693, ABclonal) and β-actin (AC026, ABclonal).

Techniques: Knockdown, Immunohistochemical staining, Staining, TUNEL Assay, Injection, Control

Journal: Journal of Translational Medicine

Article Title: DKC1: a robust prognostic factor and potential therapeutic target in multiple myeloma

doi: 10.1186/s12967-026-07916-6

Figure Lengend Snippet: ATF5 is the potential downstream effector of DKC1 in MM cells. A Volcano plot of differentially expressed mRNAs between MOCK1 and shDKC1 RPMI8226 cells. B Venn diagram showing overlapping genes from GO enrichment analysis between MOCK1 and shDKC1 cells involved in apoptosis and cell proliferation pathways. C Heatmap of the top 30 overlapping genes identified from GO enrichment analysis, shown with three replicates per group. D Scatter plot showing the relationship between ATF5 and DKC1 mRNA expression, using data from the MMRF CoMMpass dataset. E, F ATF5 mRNA expression ( E ) and ATF5 protein levels ( F ) in DKC1 knockdown and overexpression cells, compared to their respective control groups. G, H mRNA stability assay showing the decay rate of ATF5 mRNA in MOCK1 and shDKC1 cells. I RIP assay showing DKC1 binding to ATF5 mRNA. Data are presented as mean ± SD from three independent experiments, each with three technical replicates (wells) for qPCR. Abbreviations: gene ontology (GO)

Article Snippet: The following primary antibodies were used: DKC1 (A4407, ABclonal, Wuhan, China), ATF5 (AP0692, ABclonal), Bax (5023S, CST, Danvers, MA, USA), Bcl-2 (A19693, ABclonal) and β-actin (AC026, ABclonal).

Techniques: Expressing, Knockdown, Over Expression, Control, Stability Assay, Binding Assay

Journal: Journal of Translational Medicine

Article Title: DKC1: a robust prognostic factor and potential therapeutic target in multiple myeloma

doi: 10.1186/s12967-026-07916-6

Figure Lengend Snippet: ATF5 rescues the cellular phenotypes induced by DKC1 knockdown in MM cells. A, B EdU assay ( A ) and soft agar colony formation assay ( B ) were performed in MOCK1, shDKC1, and shDKC1+oeATF5 groups, alongside MOCK2, oeDKC1, and oeDKC1+shATF5 groups. C Apoptosis analysis in MOCK1, shDKC1, and shDKC1+oeATF5 groups. D Apoptosis analysis following 72 h serum starvation in MOCK2, oeDKC1, and oeDKC1+shATF5 groups. Data are presented as mean ± SD from 3 independent experiments. E Model illustrating the DKC1–ATF5-Bcl-2 axis. Reduced DKC1 expression decreases ATF5 mRNA stability, downregulates Bcl-2, and consequently inhibits proliferation while promoting apoptosis in MM cells

Article Snippet: The following primary antibodies were used: DKC1 (A4407, ABclonal, Wuhan, China), ATF5 (AP0692, ABclonal), Bax (5023S, CST, Danvers, MA, USA), Bcl-2 (A19693, ABclonal) and β-actin (AC026, ABclonal).

Techniques: Knockdown, EdU Assay, Soft Agar Assay, Expressing